Medtronic Partners with Abbott to Integrate CGM Tech and Revive Diabetes Care Segment

Abbott and Medtronic have partnered to combine Abbott's continuous glucose monitor (CGM) technology with Medtronic's automated insulin administration devices, such the MiniMed insulin pump. Following dismal performance from its diabetes care segment since 2022, Medtronic has partnered with another large diabetic care firm for the first time. The new gadget, created by Abbott and offered by Medtronic, attempts to revive the company's diabetes care segment. Due to competition, sales of Medtronic's current diabetic treatment devices have been dropping. At the moment, patients find Medtronic's Guardian 4 sensor to be bigger, more challenging to apply, and in need of a separate transmitter in order to link to their meters or cellphones.

As to the CGM device market model developed by GlobalData, Medtronic's current share in the CGM industry is at a meagre 4.6%. In contrast, after seven years on the market, Abbott now holds 57.7% of the worldwide CGM market. As the industry moves more in the direction of the integration of devices for diabetes treatment, Abbott's experience with CGM technologies and integration may provide Medtronic a much-needed boost in market share for these devices.